 Bellerophon Therapeutics, Inc. BLPH, a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious lung diseases, today announced that the company has been added to the Russell 3000 and Microcap Indexes at the conclusion of the Russell indexes annual reconstitution, effective upon the U.S. market open today. Annual Russell indexes reconstitution captures the 4,000 largest U.S. stocks as of May 8, 2020, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000 Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index, as well as the appropriate growth and value style indexes. 